Predict your next investment

EyeYon company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
eye-yon.com

See what CB Insights has to offer

Founded Year

2011

Stage

Series C | Alive

Total Raised

$35.1M

Valuation

$0000 

Last Raised

$25M | 6 mos ago

About EyeYon

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon has developed a contact lens constructed so that it extracts fluid from the cornea, thereby relieving the edema. The lens' unique structure creates an imbalance in the concentration of ions on the side of the lens, with a higher concentration on the lens than on the cornea itself. This creates a waterfall of pressure that draws out the fluids. The lens also improves vision by smoothing the cornea and preventing the edema from making bending in the cornea.

EyeYon Headquarter Location

High-Tech Village Givat Ram Campus P.O. Box 39158

Jerusalem, 91391,

Israel

+972.2.655.3333

Latest EyeYon News

EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edema

Jun 8, 2021

EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue. Last month, the EndoArt became the only ophthalmic device in the world to receive both China’s Innovative Device Status and the Breakthrough Device Designation from the US FDA. The EndoArt is designed to replace dysfunctional endothelium in patients awaiting human donor tissue as a first-line treatment for patients with chronic corneal edema. A nonfunctioning endothelium results in excess fluid flowing into the cornea, resulting in severe vision loss, pain and irreversible scarring of the human tissue. The implant has been in clinical trials, including human clinical trials, in selected medical centers in Europe, including in IVRC in Heidelberg, Instituto de Microcirugia Ocular (IMO) in Barcelona, and AMC in Amsterdam. Other clinical trials are underway in India and Israel. With more than 13 million on the waiting list for corneal transplant, the current standard of care, the EndoArt was created in an effort to eliminate global shortages of corneal donations. “We are proud to receive CE mark for our unique EndoArt implant, which is set to transform the way patients with chronic corneal edema are treated,” Nahum Ferera, Co-Founder and CEO of EyeYon Medical, said in a company news release. “This important approval enables us to work closely with healthcare providers across Europe to help patients who suffer from corneal edema regain their sight and quality of life with a simple, accessible and cutting-edge solution. We would like to thank our European partners for the journey we shared over the past years to advance our technology in the continent.” “The EndoArt opens up a new vision for the future: availability, ease of use, and cost reduction in treating patients with endothelial failure,” commented Ruth Lapid-Gortzak MD, PhD, trial Principal Investigator from the Amsterdam University Medical Centers, one of the centers leading in-human trials of the EndoArt implant in Europe. “Our trials have demonstrated decrease in corneal thickness in all patients; and in patients with visual potential, there has been an improvement in visual acuity with no evidence of detrimental metabolic effect in the recipient cornea. The EndoArt has clear benefits as no tissue or tissue bank is needed, and no tissue rejection issues or transmission of infections can occur. We are very excited about its addition to the arsenal of corneal surgery.” “The CE Mark clearance signifies a new milestone in our journey to transform the treatment of corneal edema across the world,” Dr. Ofer Daphna, Co-founder, Chief medical director and the inventor of the EndoArt, said in the news release. “We are pleased to provide a safe, innovative and minimally-invasive treatment option to patients with chronic corneal edema. We are confident that our solution will help eliminate the long waiting list for available human donor corneas worldwide.” Related Content

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EyeYon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EyeYon is included in 2 Expert Collections, including Eye Health.

E

Eye Health

711 items

M

Medical Devices

10,598 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

EyeYon Patents

EyeYon has filed 8 patents.

The 3 most popular patent topics include:

  • Disorders of sclera and cornea
  • Diseases of the eye and adnexa
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/8/2018

8/3/2021

Dosage forms, Drug delivery devices, Diseases of the eye and adnexa, Disorders of sclera and cornea, Contact lenses

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/8/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/3/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Drug delivery devices, Diseases of the eye and adnexa, Disorders of sclera and cornea, Contact lenses

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

EyeYon Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EyeYon Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.